Eligibility and patient selection are determined subsequent to all pertinent clinical data and a majority vote of the Institute's advisory board and is subject to all cases. Further discussion of Neuralyn TM will be presented to the World Congress of Alternative Medicine 1998 and the Association for Integrative Medicine. Recent Case Summaries Continued ten subjects. Nine of the ten subjects experienced change in clinical dynamic and presentation. One case was essentially unresponsive, qualitatively.
Volumetric measurement shows similar reactive capacity.
Initialized data is further noted. Pain levels were significantly reduced in all cases, suggesting that increased oxygen perfusion and vascular volumetric symmetry appear elemental in sensory dysfunction and myofascial syndrome. The Neuralyn TM compound then provokes excitability of a baroreceptor reflex mechanism within the vascular system when administered by transdermal method introduced into the cutis. Specific neurovascular points were determined by proximity to primary cortical receptor sites. Neurometric conduction and latency values reflected improvement in all cases.